Last updated: February 16, 2026
Overview of Product and Therapeutic Area
NDC 16571-0823 is associated with Tafasitamab (marketed as Monjuvi), a monoclonal antibody approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide. It is developed by MorphoSys and Incyte.
Approval Date: August 19, 2020 (U.S. FDA).
Indications include adult patients with certain non-Hodgkin lymphomas, primarily non-Hodgkin B-cell lymphomas.
Market Size and Demand Dynamics
Clinical Need and Epidemiology
- DLBCL accounts for approximately 30-40% of non-Hodgkin lymphomas worldwide.
- Estimated new cases in the U.S.: 20,000 annually (source: CDC, 2022).
- Treatment landscape includes chemo-immunotherapy, stem cell transplant, and newer targeted therapies.
Competitive Landscape
Major competitors for relapsed/refractory DLBCL include:
- Rituximab-based regimens.
- Polatuzumab vedotin (Polivy).
- Loncastuximab tesirine (Zynlonta).
- CAR T-cell therapies (axi-cel, tisa-cel, liso-cel).
Market entry of Tafasitamab expanded options for patients ineligible for CAR T or who relapse after initial therapy.
Market Penetration
Initial uptake has been impacted by:
- Disease prevalence.
- Physician familiarity with biologics.
- Cost considerations.
- Reimbursement policies.
Tafasitamab's adoption remains moderate but growing, especially among biotech-focused hematology-oncology providers.
Price Analysis and Projections
Current Pricing
- Average Wholesale Price (AWP): Approximately $9,250 per 20 mg vial.
- Dosing: 12 mg/kg intravenously weekly for 3 weeks, then every 3 weeks, for up to 18 cycles.
- Actual cost varies based on patient weight, number of vials, and insurance negotiations.
Cost per Treatment Course
For an average patient (70 kg):
- Initial dose: 840 mg (12 mg × 70 kg).
- Vial size: 20 mg.
- Total vials per cycle: about 42 vials (840 mg / 20 mg), depending on dose adjustments.
- Approximate cost per cycle: $389,700 (42 vials × $9,250).
- Total treatment duration: up to 18 cycles, leading to an estimated maximum set cost of $7 million per patient.
Reimbursement and discounts typically lower net prices substantially.
Price Trend and Future Projections
- 1-Year Outlook (2023-2024):
Stable pricing, with minimal decline due to limited biosimilar competition and high demand.
- Medium-Term (2025-2028):
Slight decrease anticipated due to potential biosimilar development or generic biologic entrants in the hematology space.
- Long-Term (2028+):
Price reductions possible if biosimilar or alternative agents gain approval and market share.
Influencing Factors
- Patent expiry dates: No current biosimilar approvals as of 2023.
- Regulatory decisions: Approval of biosimilars in the U.S. generally takes 7-10 years post-approval; patent protectiveness suggests minimal early price erosion.
- Policy shifts: CMS CMS pricing policies or value-based reimbursement adjustments could influence net prices.
Market Entry and Licensing Opportunities
- Collaboration with biosimilar manufacturers could alter the pricing landscape.
- Launch of combined therapies or novel formulations might impact demand and pricing.
- Geographic expansion to international markets may yield variable pricing due to local reimbursement policies.
Revenue Projections
Based on current utilization and pricing assumptions:
| Year |
Estimated Patients Treated |
Revenue (at current prices) |
Comments |
| 2023 |
2,000 |
$390 million |
Market growth, new indications |
| 2024 |
2,500 |
$620 million |
Increased adoption |
| 2025 |
3,000 |
$930 million |
Biosimilar emergence begins |
| 2026 |
3,200 |
$990 million |
Accelerated market penetration |
Risks to Projections
- Market penetration could lag due to reimbursement barriers.
- Competition from biosimilars or alternative treatments.
- Regulatory changes affecting pricing or market access.
Key Takeaways
- NDC 16571-0823 (Tafasitamab) holds a significant share in the relapsed/refractory DLBCL market.
- Current average vial prices are around $9,250, with treatment costs exceeding several hundred thousand dollars per patient annually.
- Market growth hinges on evolving therapeutic options and biologic biosimilar competition.
- Price stability is expected in the short term, with potential declines in the next 4-5 years due to biosimilar development and policy dynamics.
FAQs
1. What is the primary inflow of revenue for Tafasitamab?
Revenue comes from treatment courses in relapsed/refractory DLBCL patients, mainly via hospital-based purchase agreements, with variations due to discounts and insurance negotiations.
2. How soon could biosimilar competition impact prices?
Biosimilar approvals in the U.S. typically occur 7 to 10 years after original biologic approval; with Tafasitamab approved in 2020, biosimilars may enter around 2027–2030.
3. Are there off-label uses influencing market size?
Currently, no significant off-label uses are documented, limiting off-label sales impact on the market size.
4. What are potential market entry barriers for biosimilars?
Patent protections, manufacturing complexities, and regulatory hurdles delay biosimilar entry, maintaining current price levels.
5. How do reimbursement policies affect net pricing?
Reimbursement policies and negotiated discounts significantly influence actual prices received, often lowering the list price by 50% or more.
References
[1] FDA. "Tafasitamab (Monjuvi) Label." 2020.
[2] CDC. "Lymphoma Statistics." 2022.
[3] EvaluatePharma. "Biologics Price Trends." 2023.
[4] National Cancer Institute. "Diffuse Large B-Cell Lymphoma." 2021.
